302 related articles for article (PubMed ID: 1865201)
1. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
Mouradian MM; Heuser IJ; Baronti F; Giuffra M; Conant K; Davis TL; Chase TN
J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
[TBL] [Abstract][Full Text] [Related]
2. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
4. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
5. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
Jenner P; Katzenschlager R
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
[TBL] [Abstract][Full Text] [Related]
7. Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
Jenner P; Falup-Pecurariu C; Leta V; Verin M; Auffret M; Bhidayasiri R; Weiss D; Borovečki F; Jost WH
J Neural Transm (Vienna); 2023 Nov; 130(11):1337-1347. PubMed ID: 37210460
[TBL] [Abstract][Full Text] [Related]
8. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
Antonini A; Jost WH
Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
[TBL] [Abstract][Full Text] [Related]
9. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
10. [Drug therapy in Parkinson's disease].
van Hilten JJ; Roos RA
Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
[TBL] [Abstract][Full Text] [Related]
11. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Chase TN
Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
[TBL] [Abstract][Full Text] [Related]
12. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].
Friedman A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S10-3. PubMed ID: 17941453
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
[TBL] [Abstract][Full Text] [Related]
14. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
Merello M; Lees AJ
J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
[TBL] [Abstract][Full Text] [Related]
15. [The concept of continuous dopaminergic stimulation in the treatment of late stages of Parkinson's disease].
Titova NV; Katunina EA
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):105-12. PubMed ID: 24596973
[No Abstract] [Full Text] [Related]
16. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
17. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
Schelosky L; Poewe W
Acta Neurol Scand Suppl; 1993; 146():46-9. PubMed ID: 8101415
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine tolerance in Parkinson's disease: lack of a dose effect.
Gancher ST; Woodward WR; Nutt JG
Clin Neuropharmacol; 1996 Feb; 19(1):59-64. PubMed ID: 8867518
[TBL] [Abstract][Full Text] [Related]
19. Continuous dopaminergic stimulation in Parkinson's disease.
Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
[TBL] [Abstract][Full Text] [Related]
20. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]